Release top line data for the CERPASS clinical trial

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 19 May 2022
Due: 31 Mar 2023
Checked: 1 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“top line data expected Q1 2023”

SourceReplimune Group, Inc. Form 8-K press release, 2022-05-19
FilingSEC filing index
Deadline as statedQ1 2023
Deadline used31 Mar 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-REPL-002673
Cite as https://keptindex.org/c/KI-C-2022-REPL-002673/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not release the CERPASS clinical trial top line data by the Q1 2023 deadline, subsequently delaying the expected release date to Q3 2023 and later to Q4 2023.

A
Replimune Group, Inc. 10-K filed 2023-05-18 Regulatory filing · published 18 May 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 6cc260d709a6
“As reported in February 2023, topline data from the CERPASS trial is expected to be announced in Q3 2023.” ✓ confirmed on the page
A
Replimune Group, Inc. 10-Q filed 2023-08-03 Regulatory filing · published 3 Aug 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 671801c8d57e
“Topline data from the CERPASS trial is now expected to be announced in early Q4 2023, updated from Q3 2023” ✓ confirmed on the page

Market reaction: the shares moved +0.2% against the S&P 500 over the three sessions around the disclosure (17 May 2023 to 22 May 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +183 days
2 versions

Version 1 · original · stated 19 May 2022

Deadline 31 Mar 2023 (“Q1 2023”) · wording expected
Version 2 · stated 18 May 2023

Deadline 30 Sep 2023 (“Q3 2023”) · wording firm

“The Company remains on track to announce top line data from its registration-directed CERPASS clinical trial in Q3 2023”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Release
Deliverable: CERPASS clinical trial top line data
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.